SHERIDAN, WYOMING – May 6, 2025 – GE HealthCare (Nasdaq: GEHC) has announced a strategic expansion of its radiation oncology solutions, unveiling a suite of AI-driven technologies at the ESTRO 2025 Congress in Vienna, Austria. These developments are designed to streamline oncology workflows, accelerate treatment timelines, and improve clinical outcomes—addressing critical priorities in modern cancer care.
With cancer continuing to rank among the world’s leading causes of death, GE HealthCare is positioning itself at the forefront of oncology innovation. The company’s new solutions—ranging from AI-enabled organ segmentation to advanced MR-only radiotherapy workflows—aim to equip clinicians with tools that improve efficiency, precision, and personalization in treatment planning.
Strategic Portfolio Expansion with Spectronic Medical Acquisition
Central to GE HealthCare’s expanded offerings is its intention to integrate Spectronic Medical AB’s software into its radiation oncology ecosystem. Based in Helsingborg, Sweden, Spectronic Medical specializes in advanced image analysis designed to support more accurate and efficient radiotherapy.
Key benefits of Spectronic’s MRI Planner include:
- FDA 510(k) clearance and CE-marked technology.
- AI-based generation of synthetic CT images from standard MR scans.
- Support for MR-only workflows in brain, head-neck, and pelvic regions.
- Enhanced treatment planning precision and workflow optimization.
"Spectronic Medical was founded on the vision that advanced MRI and AI technologies can unlock entirely new possibilities in radiotherapy,” said Dr. Carl Siversson, CEO, Spectronic Medical. “Our MRI-only radiotherapy planning innovations, amplified by GE HealthCare’s global reach and clinical depth, aim to support the evolution toward more precise, personalized, and accessible cancer care."
This planned integration is expected to complement existing GE HealthCare solutions such as the AIR™ RT Coil Suite and AI-powered tools including AIR™ Recon DL and MR Contour DL, enabling a complete AI-enhanced, MR-guided radiotherapy workflow.
“We’re committed to advancing MR imaging capabilities in radiation therapy to deliver more accurate and precise care,” added Kelly Londy, president and CEO of MR at GE HealthCare.
New FDA-Cleared AI Model Enhances Contouring Accuracy
GE HealthCare also announced FDA 510(k) clearance of MR Contour DL, a deep learning-based model for organ at risk (OAR) segmentation. This model is capable of identifying 37 critical organs and anatomical structures in the head-neck and pelvic areas from standard MR imaging.
By automating what has traditionally been a manual process, MR Contour DL offers:
- Increased consistency and accuracy in treatment planning.
- Reduced diagnostic and contouring time.
- Seamless integration with GE HealthCare’s iRT digital solution.
Combined with Spectronic Medical’s MRI Planner, the AIR RT Coil Suite, and AIR Recon DL, MR Contour DL empowers a fully integrated, AI-driven MR-only simulation workflow—advancing the precision of radiation therapy planning.
Intelligent Radiation Therapy (iRT) Enhanced with AI and MR Integration
GE HealthCare’s updated Intelligent Radiation Therapy (iRT) platform showcases major upgrades aimed at transforming oncology care delivery. Enhancements include:
- A new orchestrator enabling simultaneous third-party AI application integration.
- Embedded MR imaging workflows for faster, more detailed simulation compared to traditional CT, particularly for brain, head-neck, and pelvic cancers.
These upgrades are designed to help standardize complex workflows, reduce the time from diagnosis to treatment, and ultimately improve patient outcomes.
“Cancer cases are expected to continue to rise, but the silver lining is that survival rates for various cancers have been increasing due to advancements in medical technologies, early detection and improved treatment protocols,” said Dr. Ben Newton, general manager, Oncology at GE HealthCare. “GE HealthCare is at the forefront of the battle against cancer and the expansion of our radiation oncology portfolio as well as the new AI-enabled innovations highlighted at ESTRO this year are a testament to the investments and efforts we are making to continue the key upward trend of survival following a cancer diagnosis.”
Driving the Future of Precision Oncology
GE HealthCare’s new developments underscore its long-term commitment to innovation in radiation oncology. By aligning cutting-edge AI tools with MR-based imaging workflows, the company is enabling providers to deliver more targeted and efficient cancer care—addressing both rising global demand and the push for higher treatment quality.
To explore these innovations and more at ESTRO 2025, visit GE HealthCare’s ESTRO event page or stop by booths #300 and #340.